(202) 688 0222
CME Coalition
  • Home
  • About
    • Members
    • Staff
    • FAQ
  • Issues
    • The Value of CME
    • COVID-19
    • Health Disparities
    • Quality Improvement CME
    • Shared Decision-Making
    • Open Payments
    • CME vs. Marketing
  • Resources
    • Webinars
    • Code of Conduct
    • Privacy Policies
  • Membership
    • What We Do
    • Prospectus
    • Join the Coalition
  • CME in the News
  • Contact

CME Submits Public Comments on FDA Opioid REMS

6/3/2016

 
On May 3-4, 2016, the Food and Drug Administration (FDA) hosted a two-day long Joint Meeting of the Drug Safety and Risk Management Advisory Committee (DSaRM) and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to discuss results from assessments of the extended-release and long-acting (ER/LA) Opioid Analgesics REMS.  The CME Coalition submitted public comments following the meeting, emphasizing that ​FDA should consider standardizing the REMS process, while allowing more flexibility in content. The Coalition also suggested that REMS should be expanded to include short acting opioids. 
As detailed further in the formal comments, the Coalition emphasized that "the strength of CME is that it can produce myriad educational activities that are targeted to physicians based on their professional practice gaps, individualized needs, and stages of learning and change. Added flexibility will allow prescriber education to better address individual prescribers’ educational and practice needs. The effectiveness of REMS can also be measured in terms of how successfully it promotes access to education and draws the attention of the medical profession to a problem."

"... While extended release and long acting opioids can be abused, short acting opioids are even more likely to be abused and therefore, much more difficult to manage. We agree with the FDA’s stated position that REMS be expanded to SA-IR, and create a single blueprint for all opioids. We are encouraged that the FDA sees CME as a valuable tool in combatting the opioids epidemic. Our members have created hundreds of hours of pain education programs and have delivered them to hundreds of thousands of physicians. Through their research and experience, we believe that, rather than requiring the whole three to six hours of content outlined in the blueprint, that counting credit hours towards a goal of three hours of REMS education should be considered."
CME Opioid REMS - Comments to FDA
File Size: 507 kb
File Type: pdf
Download File


Comments are closed.

About

Mission
Government Affairs
Issues
Members
Staff
FAQ

Membership

Why Join
Testimonials
Join the Coalition

Resources

Sunshine Act
REMS
Commercial Logo Use
Privacy Policies
Code of Conduct

Newsroom

Press Releases
CME in the News
Blog
Picture
Copyright © 2014 CME Coalition | 1720 Eye St. NW, Washington DC | clamond@thornrun.com